Please use a PC Browser to access Register-Tadawul
Merck to create separate cancer business to offset Keytruda patent loss, WSJ reports
Merck & Co., Inc. -0.24%
Merck & Co., Inc. MRK | 115.79 | -0.24% |
Feb 23 (Reuters) - Drugmaker Merck MRK.N is separating its human-health business into two divisions to offset pressures related to the patent loss of its top-selling drug Keytruda, the Wall Street Journal reported on Monday.
One division will house its cancer drugs, including Keytruda, while the other will sell its non-cancer products.
Merck did not respond to a Reuters request for comment immediately.


